Literature DB >> 8406993

Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549.

F Bennis1, G Favre, F Le Gaillard, G Soula.   

Abstract

HMG-CoA reductase catalyzes the synthesis of mevalonate, a crucial intermediate in the biosynthesis of cholesterol and non-sterol isoprenoid compounds essential for cell growth. The HMG-CoA reductase activity of the A549 tumor cell line is higher than that of normal human fibroblasts. This deregulation in mevalonate needs was not due to an alteration in the activated state of the enzyme by short-term regulation. We show that the HMG-CoA reductase in A549 cell line was subject to a multivalent feedback control. A high fraction (40%) of the reductase activity was devoted to non-sterol products. In contrast, normal fibroblasts had only 15-20% of the reductase activity that generated non-sterol products. We also show that cholesterol and at least one of the non-sterol products are necessary for optimal cell growth of A549 cells. Our data strongly suggest that A549 cells produce more non-sterol substances which may be related to increased requirements of mevalonate for upregulated cell growth.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8406993     DOI: 10.1002/ijc.2910550421

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  Mevalonate is essential for growth of porcine and human vascular smooth muscle cells in vitro.

Authors:  G Rogler; K J Lackner; G Schmitz
Journal:  Basic Res Cardiol       Date:  1995 Nov-Dec       Impact factor: 17.165

2.  Tyrosine kinase-dependent modulation of 3-hydroxy-3-methylglutaryl-CoA reductase in human breast adenocarcinoma SKBR-3 cells.

Authors:  R Asslan; A Pradines; G Favre; F Le Gaillard
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

3.  Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents.

Authors:  Ying Chun Li; Mi Jung Park; Sang-Kyu Ye; Chul-Woo Kim; Yong-Nyun Kim
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

Review 4.  Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation.

Authors:  Sherry S Agabiti; Yilan Liang; Andrew J Wiemer
Journal:  Mol Membr Biol       Date:  2016-08-18       Impact factor: 2.857

5.  Simvastatin stimulates apoptosis in cholangiocarcinoma by inhibition of Rac1 activity.

Authors:  Timothy Miller; Fuquan Yang; Candace E Wise; Fanyin Meng; Sally Priester; Md Kamruzzaman Munshi; Micheleine Guerrier; David E Dostal; Shannon S Glaser
Journal:  Dig Liver Dis       Date:  2011-02-21       Impact factor: 4.088

6.  Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis.

Authors:  E S Istvan; M Palnitkar; S K Buchanan; J Deisenhofer
Journal:  EMBO J       Date:  2000-03-01       Impact factor: 11.598

7.  Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins.

Authors:  Jean-Pierre H Perchellet; Elisabeth M Perchellet; Kyle R Crow; Keith R Buszek; Neil Brown; Sampathkumar Ellappan; Ge Gao; Diheng Luo; Machiko Minatoya; Gerald H Lushington
Journal:  Int J Mol Med       Date:  2009-11       Impact factor: 4.101

Review 8.  Multitasking of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor: beyond cardiovascular diseases.

Authors:  Paolo Calabro; Edward T H Yeh
Journal:  Curr Atheroscler Rep       Date:  2004-01       Impact factor: 5.113

9.  Effects of pravastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, on two human tumour cell lines.

Authors:  A Gebhardt; A Niendorf
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

10.  Regulation of cholesterol synthesis in four colonic adenocarcinoma cell lines.

Authors:  S R Cerda; J Wilkinson; S A Broitman
Journal:  Lipids       Date:  1995-12       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.